Bisphosphonate therapy in the oncology setting

Expert Opinion on Emerging Drugs

Volumn 8, Issue 2, 2003, Pages 469-488

  Lipton, Allan ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Bone metastases; Clodronate; Malignant bone disease; Osteoblastic; Osteolytic; Pamidronate; Solid tumours; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; ETIDRONIC ACID; FLUOROURACIL; GLUCOCORTICOID; GONADORELIN AGONIST; GOSERELIN; IBANDRONIC ACID; LEUPRORELIN; LEXIDRONAM SAMARIUM SM 153; METHOTREXATE; PAMIDRONIC ACID; RADIOISOTOPE; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SODIUM DIHYDROGEN PHOSPHATE; SODIUM DIHYDROGEN PHOSPHATE P 32; STRONTIUM CHLORIDE; STRONTIUM CHLORIDE SR 89; TAMOXIFEN; TAMOXIFEN CITRATE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; BONE METASTASIS; BONE PAIN; BONE REMODELING; BONE TURNOVER; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIARRHEA; DIET SUPPLEMENTATION; DRUG BIOAVAILABILITY; DRUG COST; DYSPNEA; ESOPHAGUS DISEASE; FATIGUE; FEVER; FRACTURE; HEADACHE; HEALTH CARE COST; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; MULTIPLE MYELOMA; MUSCLE WEAKNESS; MYALGIA; NAUSEA; OSTEOLYSIS; PALLIATIVE THERAPY; PERIPHERAL EDEMA; PROSTATE CANCER; REVIEW; SOLID TUMOR; SPINAL CORD COMPRESSION; STOMACH DISEASE; VOMITING;

ADMINISTRATION, ORAL; BONE NEOPLASMS; CLINICAL TRIALS; CLODRONIC ACID; DIPHOSPHONATES; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS;

EID: 0346186206     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.8.2.469     Document Type: Review

References (120)

1. COLEMAN RE: Skeletal complications of malignancy. Cancer (1997) 80(8 Suppl.):1588-1594. This review summarises the prevalence of bone lesions in patients with cancer and describes the skeletal complications that often result.
2. SAAD F, GLEASON D, MURRAY R et al.: Zoledronic acid improves markers of bone resorption and bone formation in prostate cancer patients with osteoblastic bone metastases. Third North American Symposium on Skeletal Complications of Malignancy. Bethesda, USA (2002).
3. PARFITT AM: Bone remodeling, normal and abnormal: a biological basis for the understanding of cancer-related bone disease and its treatment. Can. J. Oncol. (1995) 5(Suppl. 1):1-10. This review explains the underlying pathophysiology of skeletal complications of malignancy.
4. PFEILSCHIFTER J, DIEL IJ: Osteoporosis due to cancer treatment: pathogenesis and management. J. Clin. Oncol. (2000) 18(7):1570-1593. This review summarises the current understanding of cancer treatment-induced bone loss and explains the expanding problems it may present.
5. BERRUTI A, DOGLIOTTI L, GORZEGNO G et al.: Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin. Chem. (1999) 45(8 Pt. 1):1240-1247.
6. FERLAY J, BRAY F, PISANI P, PARKIN DM: GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC CancerBase No. 5. IARC Press, Lyon, France (2001).
7. GREENLEE RT, HILL-HARMON MB, MURRAY T, THUN M: Cancer statistics, 2001. [published erratum in CA. Cancer J. Clin. (2001) 51(2):144]. CA. Cancer J. Clin. (2001) 51(1):15-36.
8. GREENLEE RT, HILL-HARMON MB, MURRAY T, THUN M: Cancer statistics, 2001. [published erratum in CA. Cancer J. Clin. (2001) 51(2):144]. CA. Cancer J. Clin. (2001) 51(1):15-36.
9. COLEMAN RE: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. (2001) 27(3):165-176. This review explains the identification and characterisation of bone lesions, available therapies, and possible complications.
10. BERRUTI A, DOGLIOTTI L, BITOSSI R et al.: Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J. Urol. (2000) 164(4):1248-1253. This review underscores the high prevalence of skeletal morbidity in patients with prostate cancer and gives insight into the underlying pathophysiology.
11. MERCADANTE S: Malignant bone pain: pathophysiology and treatment. Pain (1997) 69(1-2):1-18. This review explains the scope of the problems created by metastatic bone disease, why the symptoms are so severe, and the challenges of treating patients with bone pain from malignancies.
12. WEINFURT KP, LI Y, CASTEL LD, TIMBIE JW, GLENDENNING A, SCHULMAN KA: The impact of skeletal-related events on health-related quality of life of patients with metastatic prostate cancer. Ann. Oncol. (2002) 13(Suppl. 5):180 (Abstract #662P).
13. BERENSON JR, LICHTENSTEIN A, PORTER L et al.: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J. Clin. Oncol. (1998) 16(2):593-602. This trial established the long-term safety and efficacy of pamidronate in patients with osteolytic bone lesions from multiple myeloma.
14. ROSEN LS, GORDON D, TCHEKMEDYIAN S et al.: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A Phase III, double-blind, randomized trial-The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J. Clin. Oncol. (2003) 21:3150-3157. This trial provides the first objective and significant evidence of a bisphosphonate reducing the risk of skeletal morbidity in patients with solid tumours other than breast or prostate cancer. These findings established zoledronic acid as a standard of care in this setting.
15. TCHEKMEDYIAN S, ROSEN LS, GORDON D et al.: Long-term efficacy and safety of zoledronic acid in reducing skeletal complications in patients with bone metastases from solid tumors. Proc. Am. Soc. Clin. Oncol. (2003) 22:630 (Abstract #2532). The extension (21-month) data from a 9-month Phase III clinical trial, these results establish the long-term efficacy and safety of zoledronic acid in patients with lung cancer and other solid tumours.
16. SAAD F, GLEASON D, MURRAY R et al.: Zoledronic acid is well tolerated for up to 24 months and significantly reduces skeletal complications in patients with advanced prostate cancer metastatic to bone. Annual Meeting of the American Urological Association. Chicago, USA (2003) (Abstract #1472). The extension (24-month) data from a 15-month Phase III clinical trial, these results show the long-term efficacy and safety of zoledronic acid in patients with prostate cancer.
17. LIPTON A, THERIAULT RL, HORTOBAGYI GN et al.: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer (2000) 88(5):1082-1090. This trial established the long-term safety and efficacy of pamidronate in patients with osteolytic lesions from breast cancer.
18. DELEA T, MCKIERNAN J, LISS M et al.: Cost of skeletal complications in patients with multiple myeloma. IXth Annual International Workshop on Multiple Myeloma. Salamanca, Spain (2003) (Poster #P247). This study highlights the economic impact of skeletal morbidity in patients with multiple myeloma.
19. MCKIERNAN J, LISS M, EDELSBERG J et al.: Cost of skeletal complications in patients with bone metastases of solid tumors. ECCO 12 - the European Cancer Conference Copenhagen, Denmark (2003). This study highlights the economic impact of skeletal morbidity in patients with bone metastases from solid tumours.
20. MCKIERNAN J, LISS M, EDELSBERG J et al.: Cost of skeletal complications in patients with bone metastases of lung cancer. 10th World Conference on Lung Cancer. Vancouver, Canada (2003). This study highlights the economic impact of skeletal morbidity in patients with lung cancer.
21. GROOT MT, BOEKEN KRUGER CG, PELGER RC, UYL-DE GROOT CA: Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur. Urol. (2003) 43(3):226-232. This study highlights the economic impact of skeletal morbidity in patients with prostate cancer.
22. GROOT MT, HUIJGENS PC, WIJERMANS PJ, UYL-DE GROOT CA: Costs of multiple myeloma and associated skeletal-related events in the Netherlands. 8th Congress of the European Hematology Association. Lyon, France (2003). This study highlights the economic impact of skeletal morbidity in patients with multiple myeloma.
23. HARRINGTON KD: Orthopedic surgical management of skeletal complications of malignancy. Cancer (1997) 80(8 Suppl.):1614-1627.
24. FOURNEAU I, BROOS P: Pathologic fractures due to metastatic disease. A retrospective study of 160 surgically treated fractures. Acta Chir. Belg. (1998) 98(6):255-260.
25. SERAFINI AN: Therapy of metastatic bone pain. J. Nucl. Med. (2001) 42(6):895-906. This review provides treatment strategies for severe bone pain, the most common skeletal complication of malignancy.
26. GIAMMARILE F, MOGNETTI T, RESCHE I: Bone pain palliation with strontium-89 in cancer patients with bone metastases. Q. J. Nucl. Med. (2001) 45(1):78-83.
27. THERIAULT RL, HORTOBAGYI GN: The evolving role of bisphosphonates. Semin. Oncol. (2001) 28:284-290.
28. GREEN JR, CLEZARDIN P: Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am. J. Clin. Oncol. (2002) 25(6 Suppl. 1):S3-S9.
29. LAHTINEN R, LAAKSO M, PALVA I, VIRKKUNEN P, ELOMAA I: Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma [published erratum appears in Lancet (1992) 340(8832):420]. Finnish Leukaemia Group. Lancet. (1992) 340(8827):1049-1052.
30. LAHTINEN R, LAAKSO M, PALVA I, VIRKKUNEN P, ELOMAA I: Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma [published erratum appears in Lancet (1992) 340(8832):420]. Finnish Leukaemia Group. Lancet. (1992) 340(8827):1049-1052.
31. MCCLOSKEY EV, MACLENNAN IC, DRAYSON MT, CHAPMAN C, DUNN J, KANIS JA: A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br. J. Haematol. (1998) 100(2):317-325.
32. PATERSON AH, POWLES TJ, KANIS JA, MCCLOSKEY E, HANSON J, ASHLEY S: Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J. Clin. Oncol. (1993) 11(1):59-65.
33. FLEISCH H: Bisphosphonates: mechanisms of action. Endocr. Rev. (1998) 19(1):80-100.
34. LIPTON A, ZHENG M, SEAMAN J: Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer (2003) 98:962-969.
35. SAAD F, GLEASON DM, MURRAY R et al.: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl. Cancer Inst. (2002) 94:1458-1468. This 15-month trial was the first demonstration of a bisphosphonate providing objective and significant decreases in skeletal morbidity in patients with prostate cancer, and established zoledronic acid as a standard of care in this setting.
36. NO AUTHORS LISTED: Novartis Pharmaceuticals Corporation. Aredia® [package insert]. East Hanover, NJ (2002).
37. BODY JJ, BARTL R, BURCKHARDT P et al.: Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J. Clin. Oncol. (1998) 16(12):3890-3899. This review summarises the standard therapies for treating malignant bone disease in patients with a variety of primary malignancies.
38. PECHERSTORFER M, HERRMANN Z, BODY JJ et al.: Randomized Phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J. Clin. Oncol. (1996) 14(1):268-276. This study describes the efficacy of ibandronate in treating hypercalcaemia of malignancy, an application for which it is currently approved in Europe.
39. MAJOR P, LORTHOLARY A, HON J et al.: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J. Clin. Oncol. (2001) 19(2):558-567. This trial established that zoledronic acid is more effective than pamidronate, the former standard of care, in treating patient with hypercalcaemia of malignancy.
40. MAJOR PP, LIPTON A, BERENSON J, HORTOBAGYI G: Oral bisphosphonates: a review of clinical use in patients with bone metastases. Cancer (2000) 88(1):6-14.
41. BODY JJ: Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer (2003) 97(3 Suppl.):859-865.
42. DELMAS PD, CHARHON S, CHAPUY MC et al.: Long-term effects of dichloromethylene diphosphonate (Cl2MDP) on skeletal lesions in multiple myeloma. Metab. Bone Dis. Relat. Res. (1982) 4(3):163-168.
43. KANIS JA, MCCLOSKEY EV: Bisphosphonates in multiple myeloma. Cancer (2000) 88(12 Suppl.):3022-3032. This article reviews the use of bisphosphonates in patients with multiple myeloma.
44. ELOMAA I, BLOMQVIST C, GROHN P et al.: Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet (1983) 1(8317):146-149.
45. ELOMAA I, BLOMQVIST C, PORKKA L, LAMBERG-ALLARDT C, BORGSTROM GH: Treatment of skeletal disease in breast cancer: A controlled clodronate trial. Bone. (1987) 8(Suppl. 1):S53-S56.
46. MAJOR PP, COOK R: Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am. J. Clin. Oncol. (2002) 25(6 Suppl. 1):S10-S18. This review article discusses the limitations of popular analyses of skeletal morbidity in clinical trials of bisphosphonates, and reviews the relative efficacy of different bisphosphonates.
47. KRISTENSEN B, EJLERTSEN B, GROENVOLD M, HEIN S, LOFT H, MOURIDSEN HT: Oral clodronate in breast cancer patients with bone metastases: a randomized study. J. Intern. Med. (1999) 246(1):67-74.
48. ADAMI S, SALVAGNO G, GUARRERA G et al.: Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J. Urol. (1985) 134(6):1152-1154.
49. ADAMI S: Bisphosphonates in prostate carcinoma. Cancer (1997) 80(8 Suppl.):1674-1679.
50. CRESSWELL SM, ENGLISH PJ, HALL RR, ROBERTS JT, MARSH MM: Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer. Br. J. Urol. (1995) 76(3):360-365.
51. KYLMALA T, TAMMELA TL, LINDHOLM TS, SEPPANEN J: The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer. Ann. Chir. Gynaecol. (1994) 83(4):316-319.
52. KYLMALA T, TAUBE T, TAMMELA TL, RISTELI L, RISTELI J, ELOMAA I: Concomitant i.v. and oral clodronate in the relief of bone pain-a double-blind placebo-controlled study in patients with prostate cancer. Br. J. Cancer (1997) 76(7):939-942.
53. ERNST DS, TANNOCK IF, WINQUIST EW et al.: Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J. Clin. Oncol. (2003) 21(17):3335-3342.
54. STRANG P, NILSSON S, BRANDSTEDT S et al.: The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anti-Cancer Res. (1997) 17(6D):4717-4721.
55. ROBERTSON AG, REED NS, RALSTON SH: Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J. Clin. Oncol. (1995) 13(9):2427-2430.
56. O'ROURKE N, MCCLOSKEY E, HOUGHTON F, HUSS H, KANIS JA: Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases. J. Clin. Oncol. (1995) 13(4):929-934.
57. PIGA A, BRACCI R, FERRETTI B et al.: A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy. J. Exp. Clin. Cancer Res. (1998) 17(2):213-217.
58. HORTOBAGYI GN, THERIAULT RL, PORTER L et al.: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N. Engl. J. Med. (1996) 335(24):1785-1791. This trial established pamidronate as a standard of care in patients who are receiving cytotoxic chemotherapy for breast cancer with osteolytic bone metastases.
59. THERIAULT RL, LIPTON A, HORTOBAGYI GN et al.: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lyric bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J. Clin. Oncol. (1999) 17(3):846-854. This trial established pamidronate as a standard of care in patients who are receiving cytotoxic chemotherapy for breast cancer with osteolytic bone metastases.
60. BERENSON JR, LICHTENSTEIN A, PORTER L et al.: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N. Engl. J. Med. (1996) 334(8):488-493. This trial established pamidronate as a standard of care in patients with osteolytic lesions from multiple myeloma.
61. CLARKE NW, HOLBROOK IB, MCCLURE J, GEORGE NJ: Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study. Br. J. Cancer (1991) 63(3):420-423.
62. SMALL EJ, SMITH MR, SEAMAN JJ, ORTU KOWALSKI M: A multicenter, randomized, placebo-controlled study of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J. Clin. Oncol. (2003) (In Press). This trial demonstrated that pamidronate has limited activity in patients with advanced prostate cancer.
63. ROSEN LS, GORDON D, KAMINSKI M et al.: Long-term efficacy of zoledronic acid compared with pamidronate disodium in treatment of skeletal complications in patients with advanced multiple myeloma or breast cancer: A randomized, double-blind, multicenter, comparative trial. Cancer 98(8):1735-1744. This 2-year extension of the 13-month core trial established that zoledronic acid is more effective than pamidronate in reducing the risk of skeletal morbidity in the overall population of patients with breast cancer or multiple myeloma and in the subset of patients with breast cancer. Zoledronic acid was safe for long-term use in this setting.
64. ROSEN LS, GORDON D, KAMINSKI M et al.: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a Phase III, double-blind, comparative trial. Cancer J. (2001) 7(5):377-387. This 13-month trial established that the efficacy and safety of zoledronic acid are at least comparable with those of pamidronate in patients with breast cancer or multiple myeloma.
65. COLEMAN RE, COOK R, MAJOR P et al.: Why is zoledronic acid superior to pamidronate for bone metastases from breast cancer but equivalent in multiple myeloma? 39th Annual Meeting of the American Society of Clinical Oncology Chicago, USA (2003) (poster #187). This analysis provides insight into the effects of cancer on bone and the interactions between bisphosphonates and bone metabolism.
66. DESHARNAIS CASTEL L, BAJWA K, MARKLE JP, TIMBIE JW, ZACKER C, SCHULMAN KA: A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support. Care Cancer. (2001) 9(7):545-551.
67. SAAD F: Treatment of bone complications in advanced prostate cancer: Rationale for bisphosphonate use and results of a Phase III trial with zoledronic acid. Semin. Oncol. (2002) 29(6 Suppl. 21):19-27.
68. SAAD F, GLEASON D, MURRAY R et al.: Long-term reduction of bone pain with zoledronic acid in patients with advanced prostate cancer metastatic to bone. American Urological Association Annual Meeting. Chicago, USA (2003) (Abstract #1473). This 24-month extension of the 15-month core trial established the long-term efficacy and safety of zoledronic acid in patients with bone metastases secondary to advanced prostate cancer.
69. THERIAULT RL: Pathophysiology of cancer treatment-induced bone loss. Evolving Role of Bisphosphonates for Cancer Treatment-Induced Bone Loss. Chicago, USA (2003).
70. MESSING E: The timing of hormone therapy for men with asymptomatic advanced prostate cancer. Urol. Oncol. (2003) 21(4):245-254.
71. WINER EP, HUDIS C, BURSTEIN HJ et al.: American Society of Clinical Oncology Technology Assessment Working Group update: Use of aromatase inhibitors in the adjuvant setting. J. Clin. Oncol. (2003) 21(13):2597-2599.
72. KANIS JA, MCCLOSKEY EV, POWLES T, PATERSON AH, ASHLEY S, SPECTOR T: A high incidence of vertebral fracture in women with breast cancer. Br. J. Cancer (1999) 79(7-8):1179-1181.
73. BAUM M, BUDZAR AU, CUZICK J et al.: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet (2002) 359(9324):2131-2139.
74. MICHAELSON D, MARUJO RR, SMITH MR: Cross-sectional analysis of markers of osteoblast and osteoclast activity in men with advanced prostate cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:379. (Abstract #1521).
75. MODI S, WOOD L, SIMINOSKI K, VENNER P: A comparison of the prevalence of osteoporosis and vertebral fractures in men with prostate cancer on various androgen deprivation therapies: preliminary report. Proc. Am. Soc. Clin. Oncol. (2001) 20:167b. (Abstract #2420).
76. HILLNER BE, INGLE JN, CHLEBOWSKI RT et al.: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J. Clin. Oncol. (2003). This article outlines the current American Society of Clinical Oncology guidelines for maintaining bone health in women during treatment for breast cancer.
77. DELMAS PD, BALENA R, CONFRAVREUX E, HARDOUIN C, HARDY P, BREMOND A: Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J. Clin. Oncol. (1997) 15(3):955-962.
78. SMITH MR, MCGOVERN FJ, ZIETMAN AL et al.: Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. (2001) 345(13):948-955.
79. SMITH MR, EASTHAM J, GLEASON DM, SHASHA D, TCHEKMEDYIAN S, ZINNER N: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J. Urol. (2003) 169(6):2008-2012. This trial established that zoledronic acid can increase bone mineral density in men during androgen deprivation therapy for early prostate cancer, a treatment that can. lead to severe bone loss.
80. GNANT M, HAUSMANINGER H, SAMONIGG H et al.: Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (± zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: results of a randomized multicenter trial. 25th Annual San Antonio Breast Cancer Symposium. San Antonio, USA (2002) (Abstract #12). This trial demonstrated that severe bone loss can occur in premenopausal women treated with hormonal therapy for breast cancer and that zoledronic acid can prevent bone loss in this setting. Furthermore, the results from this trial illustrate that tamoxifen does not preserve bone mass in premenopausal patients.
81. APARICIO A, GARDNER A, TU Y, SAVAGE A, BERENSON J, LICHTENSTEIN A: In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia. (1998) 12(2):220-229.
82. DERENNE S, AMIOT M, BARILLÉ S et al.: Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J. Bone Miner. Res. (1999) 14(12):2048-2056.
83. FROMIGUÉ O, LAGNEAUX L, BODY JJ: Bisphosphonates induce breast cancer cell death in vitro. J. Bone Miner. Res. (2000) 15(11):2211-2221.
84. SENARATNE SG, PIRIANOV G, MANSI JL, ARNETT TR, COLSTON KW: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br. J. Cancer (2000) 82(8):1459-1468.
85. TASSONE P, TAGLIAFERRI P, GALEA E, PALMIERI C, VISCOMI C, VENUTA S: Growth inhibition and apoptosis are induced by zoledronic acid on human pancreatic cancer cell lines. Proc. Am. Assoc. Cancer Res. (2002) 43:956-957 (Abstract #4736).
86. MACDONALD CD, JAYASUNDARA SG, MANSI JL, COLSTON KW: Inhibitory effects of bisphosphonates on growth of breast and lung carcinoma cells. Br. J. Cancer (2001) 85(Suppl. 1):47 (Abstract #P55).
87. GREEN J, GSCHAIDMEIER H, YONEDA T, MUNDY G: Zoledronic acid potently inhibits tumour-induced osteolysis in two models of breast cancer metastasis to bone. Ann. Oncol. (2000) 11(Suppl. 4):14 (Abstract #50P).
88. GREEN JR: Antitumor effects of bisphosphonates. Cancer (2003) 97(3):840-847.
89. DIEL IJ, SOLOMAYER EF, BASTERT G: Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies. Cancer (2000) 88(12 Suppl.):3080-3088. This review summarises the rationale and preliminary clinical evidence that bisphosphonates may inhibit the formation of metastatic bone disease.
90. MUNDY GR, YONEDA T: Bisphosphonates as anticancer drugs. N. Engl. J. Med. (1998) 339(6):398-400. This article reviews the preclinical data that suggest bisphosphonates have direct antitumour effects in addition to their inhibition of the positive feedback that occurs between cancer cells and the bone microenvironment.
91. COREY E, BROWN LG, QUINN JE et al.: Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin. Cancer Res. (2003) 9(1):295-306. This study provides preclinical evidence that zoledronic acid directly inhibits prostate cancer cell growth and the progression of osteolytic and osteoblastic bone metastases from prostate cancer (in a human xenograft model).
92. MCCLOSKEY EV, DUNN JA, KANIS JA, MACLENNAN IC, DRAYSON MT: Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br. J. Haematol. (2001) 113(14):1035-1043. This trial established the long-term efficacy of clodronate in patients with multiple myeloma.
93. HORTOBAGYI GN, THERIAULT RL, LIPTON A et al.: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J. Clin. Oncol. (1998) 16(6):2038-2044. This trial established the long-term efficacy and safety of pamidronate in patients with multiple myeloma.
94. SAAD F, LIPTON A, COLOMBO-BERRA A et al.: Zometa® (zoledronic acid) is effective in preventing and delaying skeletal events in patients with bone metastases secondary to urologic malignancies. Quebec Urological Association Meeting, Montreal, Canada (2002). This study establishes the efficacy and safety of zoledronic acid in delaying the onset of skeletal complications and reducing skeletal morbidity in patients with bone metastases secondary to prostate cancer or renal cell cancer.
95. DIEL IJ, SOLOMAYER EF, COSTA SD et al.: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med. (1998) 339(6):357-363. This trial provides evidence that, in addition to reducing skeletal morbidity from established bone metastases, bisphosphonates might be able to prevent the formation of bone metastases in patients with earlier stages of breast cancer.
96. SAARTO T, BLOMQVIST C, VIRKKUNEN P, ELOMAA I: Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J. Clin. Oncol. (2001) 19(1):10-17.
97. POWLES T, PATERSON S, KANIS JA et al.: Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J. Clin. Oncol. (2002) 20(15):3219-3224. This trial provides preliminary evidence that bisphosphonates can lower the incidence of bone metastases in patients with primary operable breast cancer.
98. DEARNALEY DP, SYDES MR, MASON MD et al.: A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J. Natl. Cancer Inst. (2003) 95(17):1300-1311.
99. HEIDENREICH A, HOFMANN R, ENGELMANN UH: The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J. Urol. (2001) 165(1):136-140.
100. RIZZOLI R, FORNI M, SCHAAD MA et al.: Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer. Bone (1996) 18(6):531-537.
101. SAARTO T, BLOMQVIST C, VALIMAKI M, MAKELA P, SARNA S, ELOMAA I: Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br. J. Cancer (1997) 75(4):602-605.
102. VEHMANEN L, SAARTO T, ELOMAA I, MAKELA P, VALIMAKI M, BLOMQVIST C: Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur. J. Cancer (2001) 37(18):2373-2378. This trial illustrates the long-term effects of ovarian ablative therapies for breast cancer on bone mineral density, and provides evidence that bisphosphonates can reduce bone loss in this setting.
103. POWLES TJ, MCCLOSKEY E, PATERSON AHG et al.: Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J. Natl. Cancer Inst. (1998) 90(9):704-708.
104. SAARTO T, BLOMQVIST C, VALIMAKI M, MAKELA P, SARNA S, ELOMAA I: Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J. Clin. Oncol. (1997) 15(4):1341-1347. This trial illustrates the effects of ovarian ablative therapies for breast cancer on bone mineral density, and provides preliminary evidence that bisphosphonates can reduce bone loss in this setting.
105. PATERSON A: Prevention of bone metastases in breast cancer. BONEFOS Satellite Symposium at the 12th ECCO Annual Meeting, Copenhagen, Denmark (2002).
106. TRIPATHY D, LAZAREV A, LICHINITSER MR, DECKER D, MCLACHLAN SA, BUDDE M: Oral ibandronate lowers the incidence of skeletal complications in breast cancer patients with bone metastases. Proc. Am. Soc. Clin. Oncol. (2002) 21:45a (Abstract #176).
107. BODY J-J, KANIS J, DIEL I, BERGSTROM B: Risk reductions in metastatic breast cancer: Multivariate poisson regression analyses of oral and i.v. ibandronate [abstract]. Proc. Am. Soc. Clin. Oncol. (2003) 22:46 (Abstract 184).
108. DIEL IJ, BODY J-J, TRIPATHY D, BERGSTROM B: Oral daily ibandronate in women with metastatic breast cancer: a pooled safety analysis. Proc. Am. Soc. Clin. Oncol. (2003) 22:47 (Abstract #186).
109. MENSSEN HD, SAKALOVA A, FONTANA A et al.: Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J. Clin. Oncol. (2002) 20(9):2353-2359.
110. HEIDENREICH A, ELERT A, HOFMANN R: Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis. (2002) 5(3):231-235.
111. WONG R, WIFFEN PJ: Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst. Rev. (2002):CD002068. This review evaluates the use of bisphosphonates in patients with malignant bone pain, and provides justification for the use of bisphosphonates as palliative therapy in patients with bone metastases.
112. MAXWELL C, SWIFT R, GOODE M, DOANE L, ROGERS M: Advances in supportive care of cancer patients with bone metastases: Nursing implications of zoledronic acid. Clin. J. Oncol. Nurs. 7(4):403-408. This Nursing Guidelines manuscript outlines the supportive care of patients being treated with bisphosphonates and reviews the recent data and regulatory approvals of zoledronic acid in patients with bone metastases.
113. BERENSON JR, HILLNER BE, KYLE RA et al.: American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J. Clin. Oncol. (2002) 20(17):3719-3736. This article summarises the consensus guidelines established by the American Society of Clinical Oncology for the use of bisphosphonates in patients with multiple myeloma.
114. HILLNER BE, INGLE JN, BERENSON JR et al.: American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J. Clin. Oncol. (2000) 18(6):1378-1391. This article summarises the consensus guidelines established by the American Society of Clinical Oncology for the use of bisphosphonates in patients with breast cancer.
115. NO AUTHORS LISTED: Novartis Pharmaceuticals Corporation. Zometa® [package insert]. East Hanover, NJ (2003).
116. BERENSON JR: Zoledronic acid in cancer patients with bone metastases: Results of Phase I and II trials. Semin. Oncol. (2001) 28(2 Suppl. 6):25-34.
117. HORTOBAGYI GN: Novel approaches to the management of bone metastases in patients with breast cancer. Semin. Oncol. (2002) 29(3 Suppl. 11):134-144. This review outlines the treatment options (including bisphosphonates) available for bone metastases secondary to breast cancer.
118. http://seer.cancer.gov/csr/1973_1999/ SEER cancer statistics review (2000).
119. http://hcup.ahrq.gov/HCUPnet.asp 2001 national statistics - cross-classifying diagnoses or procedures (2003).
120. http://www.us.zometa.com/hcp/productinfo/infusioninstructions.jsp Outpatient infusion with ZOMETA® (zoledronic acid) injection (2003).